Clinical Trials on Cefalea a grappolo

Total 4779 results

BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

Severe Haemophilia A

United Kingdom
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
University of Wisconsin, Madison
National Institute on Deafness and Other Communication Disorders (NIDCD)

Enrolling by invitation

Vitamin A Status in Patients With Vocal Fold Leukoplakia

Vitamin A Deficiency | Leukoplakia | Vitamin A | Vocal Cord Neoplasm

United States
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Prevention Trial

Hemophilia A Without Inhibitor

United States
Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Octapharma

Completed

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

Austria, United Kingdom, Bulgaria, Hungary, Germany, Poland, Romania, Slovakia
Children's Hospital Los Angeles

Withdrawn

Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography

Hemophilia A With Inhibitors
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Severe Hemophilia A

United States
Nara Medical University
Shire

Unknown

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Hemophilia A With Inhibitor

Japan
Skane University Hospital

Completed

Hemophilia Inhibitor Genetics Study (HIGS)

Hemophilia A With Inhibitor

Sweden
New York Presbyterian Hospital
Manchester University NHS Foundation Trust

Terminated

International Immune Tolerance Study

Hemophilia A With Inhibitors

United States
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Octapharma

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Severe Hemophilia A

Spain, Croatia, Italy, North Macedonia, Serbia
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Eradication Trial

Hemophilia A With Inhibitor

United States
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Children's Hospital Los Angeles
Takeda

Active, not recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Hemophilia A With Inhibitor

United States
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Completed

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (RESIST EXP)

Severe Hemophilia A

United States
Octapharma

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Severe Hemophilia A

Russian Federation, Ukraine
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
CHU de Reims

Unknown

TFPI Levels in Haemophilia A and B Patients

Haemophilia A and B

France
Octapharma

Completed

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Severe Hemophilia A

United States, Bulgaria
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
Margaret Ragni

Withdrawn

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (INHIBIT)

Severe Hemophilia A

United States
Beijing Children's Hospital

Unknown

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China (HA-LD-ITI)

Hemophilia A With Inhibitor

China
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Hospital Based Incidence of Group A Streptococcal Disease in Fiji

Streptococcus Group A

Fiji
Skane University Hospital

Completed

The Malmö International Brother Study (MIBS)

Hemophilia A With Inhibitors

Sweden
Chang Gung Memorial Hospital

Not yet recruiting

Normal Saline Versus Heparin Intermittent Flushing for the Prevention of Occlusion in Port-a-Cath

Port-a-cath Occlusion | Normal Saline | Heparin Lock
Silence Therapeutics plc

Active, not recruiting

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Cardiovascular Diseases | Atherosclerosis | Lipoprotein(a)

Australia, Czechia, Denmark, Netherlands, Slovakia, South Africa, United Kingdom
Assistance Publique Hopitaux De Marseille

Completed

Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans (PIG-A)

Patient With Breast Cancer

France
Eda Cetin Ozdemir

Completed

Volumetric Changes in Free Gingival Graft Procedures Taken With Different Techniques

Ndirectly Measuring the Difference Between the Free Gingival Graft and the Free Gingival Unit Via a Scanner

Turkey
University Hospital Plymouth NHS Trust

Terminated

Enteral Feeding in Discharged Patients

Surgical Resection of an Upper Gastrointestinal Malignancy | Nutritional Supplementation Via a Jejunostomy Post Discharge From Hospital

United Kingdom
Tri-Service General Hospital

Recruiting

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

Severe Hemophilia A Without Inhibitor

Taiwan
Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
Groupe Maladies hémorragiques de Bretagne

Recruiting

Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A (GIDEMHA)

Desmopressin | Hemophilia A, Mild | Factor VIII

France
University of Washington
Genentech, Inc.

Recruiting

Emicizumab in Patients With Acquired Hemophilia A (AHAEmi)

Acquired Hemophilia A

United States
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® (pathfinder9)

Haemophilia A

Austria, Spain, Bulgaria, Croatia, Estonia, Hungary, Italy, Lithuania, Portugal, Greece, Germany, Czechia, Slovenia, Switzerland, Slovakia
Chulalongkorn University

Completed

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

Severe Hemophilia A Without Inhibitor

Thailand
Baxalta now part of Shire

No longer available

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Acquired Hemophilia A

United States

Clinical Trials on Cefalea a grappolo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations